Seaport Global Securities Equities Analysts Boost Earnings Estimates for Seres Therapeutics, Inc. (MCRB)
Seres Therapeutics, Inc. (NASDAQ:MCRB) – Seaport Global Securities upped their FY2017 earnings estimates for Seres Therapeutics in a note issued to investors on Thursday. Seaport Global Securities analyst V. Bernardino now anticipates that the biotechnology company will post earnings of ($2.20) per share for the year, up from their prior forecast of ($2.88). Seaport Global Securities has a “Buy” rating and a $20.00 price target on the stock. Seaport Global Securities also issued estimates for Seres Therapeutics’ Q4 2017 earnings at ($0.70) EPS, FY2018 earnings at ($2.51) EPS, FY2019 earnings at ($2.44) EPS, FY2020 earnings at ($1.55) EPS and FY2021 earnings at $4.20 EPS.
A number of other research analysts also recently issued reports on the company. Zacks Investment Research downgraded Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Citigroup Inc. started coverage on Seres Therapeutics in a research note on Thursday, October 12th. They set a “positive” rating and a $19.00 price objective for the company. CIBC started coverage on Seres Therapeutics in a research note on Friday, October 13th. They set an “outperform” rating and a $19.00 price objective for the company. Oppenheimer Holdings, Inc. started coverage on Seres Therapeutics in a research note on Thursday, October 12th. They set an “outperform” rating and a $19.00 price objective for the company. Finally, ValuEngine downgraded Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, September 21st. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $18.00.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/11/14/seaport-global-securities-equities-analysts-boost-earnings-estimates-for-seres-therapeutics-inc-mcrb.html.
Seres Therapeutics (NASDAQ:MCRB) opened at $9.66 on Monday. The company has a current ratio of 6.53, a quick ratio of 6.53 and a debt-to-equity ratio of 0.11. Seres Therapeutics has a 52 week low of $8.85 and a 52 week high of $17.42.
Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.22. The business had revenue of $23.00 million during the quarter, compared to the consensus estimate of $17.29 million. Seres Therapeutics had a negative return on equity of 82.11% and a negative net margin of 267.15%. The business’s quarterly revenue was up 76.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.46) EPS.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC lifted its holdings in Seres Therapeutics by 5.8% in the 1st quarter. Geode Capital Management LLC now owns 166,325 shares of the biotechnology company’s stock worth $1,874,000 after purchasing an additional 9,060 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Seres Therapeutics by 24.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 44,418 shares of the biotechnology company’s stock worth $501,000 after purchasing an additional 8,851 shares in the last quarter. Citadel Advisors LLC lifted its holdings in Seres Therapeutics by 94.6% in the 2nd quarter. Citadel Advisors LLC now owns 40,212 shares of the biotechnology company’s stock worth $455,000 after purchasing an additional 19,550 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new position in Seres Therapeutics in the 2nd quarter worth approximately $236,000. Finally, Vanguard Group Inc. lifted its holdings in Seres Therapeutics by 7.1% in the 1st quarter. Vanguard Group Inc. now owns 1,565,663 shares of the biotechnology company’s stock worth $17,645,000 after purchasing an additional 103,456 shares in the last quarter. 74.77% of the stock is currently owned by institutional investors.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Stock Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related stocks with our FREE daily email newsletter.